This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (119)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Lost Battle?

Bernard Pécoul, MD, MPH; Pierre Chirac, PharmD; Patrice Trouiller, PharmD; Jacques Pinel, PharmD

JAMA. 1999;281:361-367.

Drugs offer a simple, cost-effective solution to many health problems, provided they are available, affordable, and properly used. However, effective treatment is lacking in poor countries for many diseases, including African trypanosomiasis, Shigella dysentery, leishmaniasis, tuberculosis, and bacterial meningitis. Treatment may be precluded because no effective drug exists, it is too expensive, or it has been withdrawn from the market. Moreover, research and development in tropical diseases have come to a near standstill. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world: (1) poor-quality and counterfeit drugs; (2) lack of availability of essential drugs due to fluctuating production or prohibitive cost; (3) need to develop field-based drug research to determine optimum utilization and remotivate research and development for new drugs for the developing world; and (4) potential consequences of recent World Trade Organization agreements on the availability of old and new drugs. These problems are not independent and unrelated but are a result of the fundamental nature of the pharmaceutical market and the way it is regulated.

Author Affiliations: Fondation Médecins Sans Frontières, Paris, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-based practices to reduce maternal mortality: a systematic review
Piane
J Public Health (Oxf) 2009;31:26-31.
ABSTRACT | FULL TEXT  

Oral Drug Therapy for Multiple Neglected Tropical Diseases: A Systematic Review
Reddy et al.
JAMA 2007;298:1911-1924.
ABSTRACT | FULL TEXT  

Use of Traditional Herbal Medicine by AIDS Patients in Kabarole District, Western Uganda
Langlois-Klassen et al.
Am J Trop Med Hyg 2007;77:757-763.
ABSTRACT | FULL TEXT  

Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence
Kelesidis et al.
J Antimicrob Chemother 2007;60:214-236.
ABSTRACT | FULL TEXT  

Pain Management: A Fundamental Human Right
Brennan et al.
Anesth. Analg. 2007;105:205-221.
ABSTRACT | FULL TEXT  

Biomedical Patents and the Public's Health: Is There a Role for Eminent Domain?
Kesselheim and Avorn
JAMA 2006;295:434-437.
FULL TEXT  

Synthesis and Antileishmanial Activities of Novel 3-Substituted Quinolines
Tempone et al.
Antimicrob. Agents Chemother. 2005;49:1076-1080.
ABSTRACT | FULL TEXT  

Comparative Activities of the Triterpene Saponin Maesabalide III and Liposomal Amphotericin B (AmBisome) against Leishmania donovani in Hamsters
Maes et al.
Antimicrob. Agents Chemother. 2004;48:2056-2060.
ABSTRACT | FULL TEXT  

TRIPS And The Global Pharmaceutical Market
Barton
Health Aff (Millwood) 2004;23:146-154.
ABSTRACT | FULL TEXT  

In Vitro and In Vivo Activities of a Triterpenoid Saponin Extract (PX-6518) from the Plant Maesa balansae against Visceral Leishmania Species
Maes et al.
Antimicrob. Agents Chemother. 2004;48:130-136.
ABSTRACT | FULL TEXT  

Orphan Diseases and Adoptive Initiatives
Iribarne
JAMA 2003;290:116-116.
FULL TEXT  

DISEASES WITHOUT BORDERS: GLOBALIZATION'S CHALLENGE TO THE AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE: A CALL FOR PUBLIC ADVOCACY AND ACTIVISM
BARRY
Am J Trop Med Hyg 2003;69:3-7.
FULL TEXT  

Case 20-2002 - A 37-Year-Old Man with Fever, Hepatosplenomegaly, and a Cutaneous Foot Lesion after a Trip to Africa
Moore et al.
NEJM 2002;346:2069-2076.
FULL TEXT  

A Globalized Theory of Public Health Law
Fidler
J Law Med Ethics 2002;30:150-161.
 

Medicalisation, limits to medicine, or never enough money to go around?
Freemantle and Hill
BMJ 2002;324:864-865.
FULL TEXT  

Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?
Attaran and Gillespie-White
JAMA 2001;286:1886-1892.
ABSTRACT | FULL TEXT  

Lifestyle drugs: issues for debate
Lexchin
CMAJ 2001;164:1449-1451.
FULL TEXT  

The Disappearing Arsenal of Antiparasitic Drugs
White
NEJM 2000;343:1273-1274.
FULL TEXT  

Lack of new drugs for tropical disease should not be accepted
Schull
BMJ 2000;321:179a-179.
FULL TEXT  

Something to Be Done: Treating HIV/AIDS
Bloom and Associates
Science 2000;288:2171-2173.
ABSTRACT | FULL TEXT  

The Global Drug Gap
Reich
Science 2000;287:1979-1981.
ABSTRACT | FULL TEXT  

Political economy of technology transfer
Donald
BMJ 1999;319:1298-1298.
FULL TEXT  

Access to Essential Drugs in Poor Countries
Kessel et al.
JAMA 1999;282:630-631.
FULL TEXT